

Global Bevacizumab Biosimilars Market Set For 7.8% Growth, Reaching \$2.09 Billion By 2028

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 19, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



The Business
Research Company

Bevacizumab Biosimilars Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033

[The bevacizumab biosimilars market has demonstrated strong growth](#) in recent years. It is set to grow from \$1.43 billion in 2023 to \$1.55 billion in 2024, reflecting a compound annual growth

rate CAGR of 8.7%. Factors like patent expiry, cost containment in healthcare, increasing incidence of cancer, market competitiveness, patient access and affordability and biosimilar acceptance have contributed to this uplift.

“

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to \$2.09 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%”

*The Business Research
Company*

The bevacizumab biosimilars market is anticipated to continue to grow. It is predicted to reach \$2.09 billion by 2028, at a CAGR of 7.8%. This growth is attributed to rising demand for cancer therapies, biosimilar development expertise, healthcare system pressures, the biosimilar regulatory landscape, and biosimilar interchangeability. The forecast period is also expected to see strides in collaborations and partnerships, regulatory advancements

and approvals, biosimilar development and innovation, market access strategies, and biosimilar lifecycle management.

Request A Sample Report For More Insightful Information:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp>

A critical driver propelling the bevacizumab biosimilars market is the increasing prevalence of cancer. Cancer incidence refers to the number of new cancer cases emerging in a specific population over a given period. Bevacizumab is a biologic that obstructs tumor angiogenesis, potentially leading to tumor shrinkage and inhibition of growth. It has shown to be comparable to reference biologics in terms of efficacy and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, Macmillan Cancer Support, a UK-based healthcare charity, forecasted in October 2022 that there were 3 million cancer patients in 2020 and that this figure is expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040.

For A Detailed Analysis Of Market Drivers, Get Your Copy Of The Report:

<https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report>

Various companies have been instrumental in the growth of the bevacizumab biosimilars market, including Cipla Limited, Reliance lifesciences Pvt. Ltd, Genentech Inc, Fujifilm Kyowa Kirin Biologics Co. Ltd, Pfizer Inc, AbbVie Inc, Amgen Inc, and other key market players.

Significant trends gaining popularity in the bevacizumab biosimilars market include product innovation. Major market players are focusing on creating innovative products to fortify their market presence. For example, in May 2022, Viatrix, a US-based pharmaceutical company, and Biocon Biologics launched Abevmy bevacizumab, a biosimilar to Roche's Avastin bevacizumab. Approved by Health Canada for use across four oncology indications, Abevmy offers similar efficacy, safety, and quality to the reference biologic and is a humanized monoclonal antibody that binds to and neutralizes the biologic action of human vascular endothelial growth factor VEGF.

[The bevacizumab biosimilars market is segmented](#) to provide a more detailed understanding. It categorizes by product into Avastin, Mvasi, Zirabev, Aybintio, and other products. By distribution channel into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels and by applications including Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, and Ovarian Cancer.

Regionally, North America was the largest market for bevacizumab biosimilars in 2023. However, the report also covers regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report>

Rituximab Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report>

Trastuzumab Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/769673726>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.